首页 > 最新文献

Journal of vascular anomalies最新文献

英文 中文
Identifying Genetic Mutations in Vascular Anomalies Using a Sequencing Panel for Childhood Cancers: A Pilot Study 利用儿童癌症测序面板识别血管异常的基因突变:试点研究
Pub Date : 2024-07-01 DOI: 10.1097/jova.0000000000000094
Elis Yuexian Lee, Y. Ang, C. Kuick, Y. Mok, Kenneth Tou En Chang, Luke Han Wei Toh, Mei Yoke Chan, Mark Jean Aan Koh
Genetic mutations have been identified in the pathogenesis of vascular anomalies. Due to overlaps in genetic variants causing vascular anomalies and cancer, we used a next-generation sequencing panel for genomic profiling of childhood cancers to detect somatic mutations in children with vascular anomalies. We aim to review the utility of an oncology panel for the molecular diagnosis of vascular anomalies. Nine patients with histologically confirmed vascular anomalies were included. DNA was extracted from formalin-fixed paraffin-embedded tissue specimens obtained from affected tissue following diagnostic punch biopsies of the skin and core biopsies of the vascular malformation or tumor during sclerotherapy or surgical excision. Molecular analysis of the tissue samples was performed using AmpliSeq for Childhood Cancer DNA Assay Panel. Two patients had antenatally detected vascular anomalies. The median age at diagnosis for the remaining patients was 7.0 years (IQR, 0.6–10.0 years). Seven were diagnosed with vascular malformations, while 2 had vascular tumors. Pathological somatic mutations were identified in 4 patients, leading to a diagnostic yield of 44.4%. Two different PIK3CA mutations were identified in 3 cases: 1 in a case of macrocystic lymphatic malformation, the other in a case of Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevus, Spinal/Skeletal anomalies syndrome and Klippel–Trenaunay syndrome. BRAF mutation was identified in a patient with a veno-lymphatic malformation. An oncology next-generation sequencing panel can be used for genetic profiling of vascular anomalies. However, a more customized and sensitive panel may be of better diagnostic yield, as detection of somatic mutations in vascular anomalies is challenging due to tissue mosaicism, low-abundant genetic variants, and specimen limitations.
在血管异常的发病机制中发现了基因突变。由于导致血管畸形和癌症的基因变异存在重叠,我们使用下一代测序小组对儿童癌症进行基因组分析,以检测血管畸形患儿的体细胞突变。我们的目的是回顾一下肿瘤面板在血管异常分子诊断中的作用。 我们纳入了九名经组织学证实的血管异常患者。从福尔马林固定石蜡包埋的组织标本中提取 DNA,这些组织标本取自诊断性皮肤打孔活检后的受影响组织,以及硬化疗法或手术切除过程中的血管畸形或肿瘤的核心活检组织。使用 AmpliSeq 儿童癌症 DNA 检测试剂盒对组织样本进行分子分析。 两名患者在出生前已发现血管畸形。其余患者确诊时的中位年龄为 7.0 岁(IQR,0.6-10.0 岁)。其中 7 人被诊断为血管畸形,2 人患有血管肿瘤。在4名患者中发现了病理体细胞突变,诊断率为44.4%。在3例患者中发现了两种不同的PIK3CA突变:其中一例是大囊淋巴畸形,另一例是先天性脂肪瘤过度生长、血管畸形、表皮痣、脊柱/骨骼异常综合征和Klippel-Trenaunay综合征。在一名静脉淋巴管畸形患者身上发现了 BRAF 基因突变。 肿瘤学新一代测序面板可用于血管异常的基因分析。然而,由于组织镶嵌、低丰度基因变异和标本限制等原因,检测血管畸形中的体细胞突变具有挑战性,因此更个性化、更灵敏的测序组可能会有更好的诊断效果。
{"title":"Identifying Genetic Mutations in Vascular Anomalies Using a Sequencing Panel for Childhood Cancers: A Pilot Study","authors":"Elis Yuexian Lee, Y. Ang, C. Kuick, Y. Mok, Kenneth Tou En Chang, Luke Han Wei Toh, Mei Yoke Chan, Mark Jean Aan Koh","doi":"10.1097/jova.0000000000000094","DOIUrl":"https://doi.org/10.1097/jova.0000000000000094","url":null,"abstract":"\u0000 \u0000 Genetic mutations have been identified in the pathogenesis of vascular anomalies. Due to overlaps in genetic variants causing vascular anomalies and cancer, we used a next-generation sequencing panel for genomic profiling of childhood cancers to detect somatic mutations in children with vascular anomalies. We aim to review the utility of an oncology panel for the molecular diagnosis of vascular anomalies.\u0000 \u0000 \u0000 \u0000 Nine patients with histologically confirmed vascular anomalies were included. DNA was extracted from formalin-fixed paraffin-embedded tissue specimens obtained from affected tissue following diagnostic punch biopsies of the skin and core biopsies of the vascular malformation or tumor during sclerotherapy or surgical excision. Molecular analysis of the tissue samples was performed using AmpliSeq for Childhood Cancer DNA Assay Panel.\u0000 \u0000 \u0000 \u0000 Two patients had antenatally detected vascular anomalies. The median age at diagnosis for the remaining patients was 7.0 years (IQR, 0.6–10.0 years). Seven were diagnosed with vascular malformations, while 2 had vascular tumors. Pathological somatic mutations were identified in 4 patients, leading to a diagnostic yield of 44.4%. Two different PIK3CA mutations were identified in 3 cases: 1 in a case of macrocystic lymphatic malformation, the other in a case of Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevus, Spinal/Skeletal anomalies syndrome and Klippel–Trenaunay syndrome. BRAF mutation was identified in a patient with a veno-lymphatic malformation.\u0000 \u0000 \u0000 \u0000 An oncology next-generation sequencing panel can be used for genetic profiling of vascular anomalies. However, a more customized and sensitive panel may be of better diagnostic yield, as detection of somatic mutations in vascular anomalies is challenging due to tissue mosaicism, low-abundant genetic variants, and specimen limitations.\u0000","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Pitfalls: Soft Tissue Lymphoma: Superficial Soft Tissue Lymphoma Mimicking a Venous Malformation 诊断陷阱:软组织淋巴瘤模仿静脉畸形的浅表软组织淋巴瘤
Pub Date : 2024-06-14 DOI: 10.1097/jova.0000000000000095
Victoire Roblot, Valérie Bousson, Annouk Bisdorff
In this case report, 3 patients addressed to our vascular anomalies reference center to manage a slow-flow vascular anomaly were reported. Our objective is to highlight that a discrepancy between clinical and radiological data should suggest a differential diagnosis and a percutaneous biopsy be considered. In our 3 patients, the biopsy provided a diagnosis of soft tissue lymphoma. Some red flags should not be overlooked to avoid missing this diagnosis, patient's past medical history of lymphoma and clinical palpation of a nondepressible hard lesion. On magnetic resonance imaging, the lesion shape and contours particularly the presence of spicules appear to be interesting features to consider lymphoma (this sign is absent in common venous malformation). Therefore, the triad past medical history and clinical and imaging data (ultrasound and MRI) are mandatory for an accurate diagnosis of vascular malformations.
在本病例报告中,我们报告了三例到血管异常参考中心就诊的慢流血管异常患者。我们的目的是强调,临床和放射学数据之间的差异应提示鉴别诊断,并考虑进行经皮活检。在我们的 3 例患者中,活检提供了软组织淋巴瘤的诊断。为避免漏诊,患者的淋巴瘤既往病史和临床触诊发现的不可压迫的硬性病变是不可忽视的信号。在磁共振成像中,病变的形状和轮廓,尤其是棘突的存在,似乎是考虑淋巴瘤的有趣特征(常见的静脉畸形则无此征象)。因此,要准确诊断血管畸形,必须结合既往病史、临床和影像学数据(超声波和核磁共振成像)。
{"title":"Diagnostic Pitfalls: Soft Tissue Lymphoma: Superficial Soft Tissue Lymphoma Mimicking a Venous Malformation","authors":"Victoire Roblot, Valérie Bousson, Annouk Bisdorff","doi":"10.1097/jova.0000000000000095","DOIUrl":"https://doi.org/10.1097/jova.0000000000000095","url":null,"abstract":"In this case report, 3 patients addressed to our vascular anomalies reference center to manage a slow-flow vascular anomaly were reported. Our objective is to highlight that a discrepancy between clinical and radiological data should suggest a differential diagnosis and a percutaneous biopsy be considered. In our 3 patients, the biopsy provided a diagnosis of soft tissue lymphoma. Some red flags should not be overlooked to avoid missing this diagnosis, patient's past medical history of lymphoma and clinical palpation of a nondepressible hard lesion. On magnetic resonance imaging, the lesion shape and contours particularly the presence of spicules appear to be interesting features to consider lymphoma (this sign is absent in common venous malformation). Therefore, the triad past medical history and clinical and imaging data (ultrasound and MRI) are mandatory for an accurate diagnosis of vascular malformations.","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141343791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidisciplinary Fusion: A recurrent expansive prevertebral vascular anomaly with EWSR1::NFATC2 fusion 多学科融合:伴有 EWSR1::NFATC2 融合的复发性膨胀性椎前血管异常
Pub Date : 2024-06-13 DOI: 10.1097/jova.0000000000000093
Samantha J. DeMarsh, Bradford Siegele, V. Zavaletta, A. Annam, Ann M. Kulungowski, Lauren R. Hill, Nathan Donaldson, Taizo A Nakano
The field of vascular anomalies has seen a rapid paradigm shift from descriptive to molecular diagnoses, with DNA-based next-generation sequencing becoming standard practice in the workup and characterization of lesions. RNA-based panels for fusion transcripts have been less utilized in the field of vascular anomalies. We report a recurrent, infiltrative prevertebral vascular tumor negative for known somatic variants but positive for an Ewing sarcoma breakpoint region 1::nuclear factor of activated T-cells cytoplasmic 2 fusion transcript. This lesion demonstrated intermediate malignant potential with morphologic atypia, novel intraluminal endothelial growth, and atypical mitoses, which have not previously been reported. RNA-based panels for fusion transcripts may represent the next impactful evolution of molecular characterization of vascular malformations and tumors.
血管异常领域的诊断模式已从描述性诊断迅速转变为分子诊断,基于 DNA 的新一代测序已成为病变检查和定性的标准做法。在血管异常领域,基于 RNA 的融合转录本检测还较少使用。我们报告了一种复发性浸润性椎前血管瘤,已知体细胞变异阴性,但尤文肉瘤断点区 1::nuclear factor of activated T-cells cytoplasmic 2 融合转录本阳性。该病变具有中度恶性潜能,形态不典型、新型腔内内皮增生和不典型有丝分裂,以前从未报道过。基于 RNA 的融合转录本检测板可能是血管畸形和肿瘤分子特征描述的下一个重要发展方向。
{"title":"Multidisciplinary Fusion: A recurrent expansive prevertebral vascular anomaly with EWSR1::NFATC2 fusion","authors":"Samantha J. DeMarsh, Bradford Siegele, V. Zavaletta, A. Annam, Ann M. Kulungowski, Lauren R. Hill, Nathan Donaldson, Taizo A Nakano","doi":"10.1097/jova.0000000000000093","DOIUrl":"https://doi.org/10.1097/jova.0000000000000093","url":null,"abstract":"The field of vascular anomalies has seen a rapid paradigm shift from descriptive to molecular diagnoses, with DNA-based next-generation sequencing becoming standard practice in the workup and characterization of lesions. RNA-based panels for fusion transcripts have been less utilized in the field of vascular anomalies. We report a recurrent, infiltrative prevertebral vascular tumor negative for known somatic variants but positive for an Ewing sarcoma breakpoint region 1::nuclear factor of activated T-cells cytoplasmic 2 fusion transcript. This lesion demonstrated intermediate malignant potential with morphologic atypia, novel intraluminal endothelial growth, and atypical mitoses, which have not previously been reported. RNA-based panels for fusion transcripts may represent the next impactful evolution of molecular characterization of vascular malformations and tumors.","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141348677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Lived Experience of Patients with Vascular Malformations: A Qualitative Meta-synthesis 血管畸形患者的生活经历:定性元综合
Pub Date : 2024-04-24 DOI: 10.1097/jova.0000000000000091
Lauren R. S. Hill, Heather Coats
The purpose of this study was to synthesize the existing qualitative literature on the lived experience of patients with vascular malformations to identify emergent themes and new areas for clinical care and research. A formal meta-synthesis was conducted, which followed 4 steps: (1) form the clinical question and refine search criteria; (2) complete a literature review following Preferred Reporting Items for Reviews and Meta-Analysis; (3) quality appraisal of included literature with Lett’s Critical Review Form; and (4) completion of team-based reciprocal translation and thematic analysis to synthesize the literature. PubMed, CINAHL, Johanna Briggs, and Embase were used to retrieve English language, peer-reviewed qualitative, and mixed-method articles from 1996 to May 2023. Six articles met the criteria for inclusion. A wide range of vascular malformations were represented, ranging from slow-flow malformation to high-flow or complex with associated overgrowth. Studies were conducted in the United States, France, and Germany, focusing mainly on the adult experience, with 1 article focusing solely on pediatrics. Three main themes emerged: social isolation, uncertainty and hope, and healthcare experiences. The overarching themes of social isolation, uncertainty and hope, and healthcare experiences each offer avenues to inform clinical practice, provide education for healthcare providers managing patients with vascular malformations, and future research to better understand how each of these themes affect patients. This qualitative meta-synthesis is a novel method for this field and provides new insights into the lived experience of those with vascular malformations.
本研究的目的是综合现有关于血管畸形患者生活经历的定性文献,以确定新出现的主题以及临床护理和研究的新领域。 我们按照以下四个步骤进行了正式的元综合:(1) 提出临床问题并完善检索标准;(2) 按照《综述和元分析首选报告项目》完成文献综述;(3) 使用莱特批判性综述表对纳入的文献进行质量评估;(4) 完成基于团队的互译和专题分析,以综合文献。我们使用 PubMed、CINAHL、Johanna Briggs 和 Embase 检索了 1996 年至 2023 年 5 月期间的英文、经同行评审的定性和混合方法文章。 六篇文章符合纳入标准。这些文章涉及多种血管畸形,包括慢流畸形、高流畸形或伴有过度生长的复杂血管畸形。研究在美国、法国和德国进行,主要关注成人的经历,其中一篇文章仅关注儿科。研究发现了三大主题:社会隔离、不确定性和希望,以及医疗保健经历。 社会隔离、不确定性和希望以及医疗保健经验这三个首要主题为临床实践提供了参考,为管理血管畸形患者的医疗服务提供者提供了教育,并为未来研究提供了途径,以更好地了解这些主题对患者的影响。这种定性元综合是该领域的一种新方法,为了解血管畸形患者的生活经历提供了新的视角。
{"title":"The Lived Experience of Patients with Vascular Malformations: A Qualitative Meta-synthesis","authors":"Lauren R. S. Hill, Heather Coats","doi":"10.1097/jova.0000000000000091","DOIUrl":"https://doi.org/10.1097/jova.0000000000000091","url":null,"abstract":"\u0000 \u0000 The purpose of this study was to synthesize the existing qualitative literature on the lived experience of patients with vascular malformations to identify emergent themes and new areas for clinical care and research.\u0000 \u0000 \u0000 \u0000 A formal meta-synthesis was conducted, which followed 4 steps: (1) form the clinical question and refine search criteria; (2) complete a literature review following Preferred Reporting Items for Reviews and Meta-Analysis; (3) quality appraisal of included literature with Lett’s Critical Review Form; and (4) completion of team-based reciprocal translation and thematic analysis to synthesize the literature. PubMed, CINAHL, Johanna Briggs, and Embase were used to retrieve English language, peer-reviewed qualitative, and mixed-method articles from 1996 to May 2023.\u0000 \u0000 \u0000 \u0000 Six articles met the criteria for inclusion. A wide range of vascular malformations were represented, ranging from slow-flow malformation to high-flow or complex with associated overgrowth. Studies were conducted in the United States, France, and Germany, focusing mainly on the adult experience, with 1 article focusing solely on pediatrics. Three main themes emerged: social isolation, uncertainty and hope, and healthcare experiences.\u0000 \u0000 \u0000 \u0000 The overarching themes of social isolation, uncertainty and hope, and healthcare experiences each offer avenues to inform clinical practice, provide education for healthcare providers managing patients with vascular malformations, and future research to better understand how each of these themes affect patients. This qualitative meta-synthesis is a novel method for this field and provides new insights into the lived experience of those with vascular malformations.\u0000","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140660092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Economic Consequences of Sirolimus Treatment in Patients With Vascular Malformations 血管畸形患者接受西罗莫司治疗的经济后果
Pub Date : 2024-04-15 DOI: 10.1097/jova.0000000000000092
Veroniek E. M. Harbers, W. Kievit, Raquel Duque Jimenez, Leo J. Schultze Kool, Ingrid M. P. van Rijnsoever, B. Verhoeven, C. V. D. van der Vleuten, D. M. W. M. te Loo
Sirolimus is one of the first oral drugs for safe and effective treatment of patients with vascular malformations, and may save (expensive) interventions. Therefore the objective was to investigate the cost-effectiveness of sirolimus in vascular malformations. This cost-effectiveness analysis from a medical and societal perspective was performed alongside a clinical phase IIB effectiveness of sirolimus in patients with vascular malformations trial. Utility and quality-adjusted life years (QALY) were calculated using the short-form six-dimension in adults and pediatric quality of life inventory scores to express effectiveness in children. Total costs included medical and productivity costs. The net monetary benefit was calculated, given a range of willingness to pay (WTP) values within societies with nationalized health care. After 6 months on sirolimus, the pediatric quality of life inventory increased by a mean of 12.10 points (95% confidence interval [CI], 7.64–16.37) in children, and the QALY increased by 0.07 (95% CI, 0.03–0.11) in adults. After 6 months on sirolimus, total costs per child were numerically increased by €110.88 (95% CI, −€1786.17–€2165.95). Per adult, sirolimus resulted in a numerical decrease of mean total cost of €426.84 (95% CI, −€2831.38–€1414.60). In adults, there was a 95% chance that sirolimus treatment would be cost-effective with a WTP of €50k per QALY gained. This first pharmacoeconomic analysis shows a substantial improvement in utility and health-related quality of life due to sirolimus treatment in patients with vascular malformations. It shows a high chance that sirolimus will be cost-effective in adults within the limits of acceptable WTP values within societies with nationalized health care. In children, sirolimus may become cost-effective in the future due to a possible decrease in interventions.
西罗莫司是首批可安全有效治疗血管畸形患者的口服药物之一,可节省(昂贵的)介入治疗费用。因此,我们的目标是研究西罗莫司治疗血管畸形的成本效益。 这项从医疗和社会角度进行的成本效益分析是与西罗莫司在血管畸形患者中的临床 IIB 期疗效试验同时进行的。在计算效用和质量调整生命年(QALY)时,使用了成人的短式六维度和儿科生活质量清单评分来表示儿童的有效性。总成本包括医疗成本和生产成本。在实行国家化医疗保健的社会中,根据支付意愿(WTP)值的范围计算出了净货币收益。 服用西罗莫司 6 个月后,儿童的儿科生活质量平均提高了 12.10 分(95% 置信区间 [CI],7.64-16.37),成人的 QALY 提高了 0.07(95% 置信区间,0.03-0.11)。服用西罗莫司 6 个月后,每名儿童的总费用增加了 110.88 欧元(95% CI,-1786.17-2165.95 欧元)。西罗莫司使每个成人的平均总费用减少了 426.84 欧元(95% CI,-2831.38-1414.60 欧元)。在成人中,西罗莫司治疗具有 95% 的成本效益,每获得 1 QALY 的 WTP 为 5 万欧元。 这项首次药物经济学分析表明,西罗莫司治疗可显著改善血管畸形患者的效用和与健康相关的生活质量。该分析表明,西罗莫司治疗成人的成本效益极有可能在国民医疗保健社会可接受的WTP值范围内。对儿童而言,由于干预措施可能减少,西罗莫司在未来可能具有成本效益。
{"title":"The Economic Consequences of Sirolimus Treatment in Patients With Vascular Malformations","authors":"Veroniek E. M. Harbers, W. Kievit, Raquel Duque Jimenez, Leo J. Schultze Kool, Ingrid M. P. van Rijnsoever, B. Verhoeven, C. V. D. van der Vleuten, D. M. W. M. te Loo","doi":"10.1097/jova.0000000000000092","DOIUrl":"https://doi.org/10.1097/jova.0000000000000092","url":null,"abstract":"\u0000 \u0000 Sirolimus is one of the first oral drugs for safe and effective treatment of patients with vascular malformations, and may save (expensive) interventions. Therefore the objective was to investigate the cost-effectiveness of sirolimus in vascular malformations.\u0000 \u0000 \u0000 \u0000 This cost-effectiveness analysis from a medical and societal perspective was performed alongside a clinical phase IIB effectiveness of sirolimus in patients with vascular malformations trial. Utility and quality-adjusted life years (QALY) were calculated using the short-form six-dimension in adults and pediatric quality of life inventory scores to express effectiveness in children. Total costs included medical and productivity costs. The net monetary benefit was calculated, given a range of willingness to pay (WTP) values within societies with nationalized health care.\u0000 \u0000 \u0000 \u0000 After 6 months on sirolimus, the pediatric quality of life inventory increased by a mean of 12.10 points (95% confidence interval [CI], 7.64–16.37) in children, and the QALY increased by 0.07 (95% CI, 0.03–0.11) in adults. After 6 months on sirolimus, total costs per child were numerically increased by €110.88 (95% CI, −€1786.17–€2165.95). Per adult, sirolimus resulted in a numerical decrease of mean total cost of €426.84 (95% CI, −€2831.38–€1414.60). In adults, there was a 95% chance that sirolimus treatment would be cost-effective with a WTP of €50k per QALY gained.\u0000 \u0000 \u0000 \u0000 This first pharmacoeconomic analysis shows a substantial improvement in utility and health-related quality of life due to sirolimus treatment in patients with vascular malformations. It shows a high chance that sirolimus will be cost-effective in adults within the limits of acceptable WTP values within societies with nationalized health care. In children, sirolimus may become cost-effective in the future due to a possible decrease in interventions.\u0000","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large Medically Resistant Intramuscular Fast-Flow Vascular Anomaly in a Young Adult Patient Managed With Embolization and Cryoablation 通过栓塞和冷冻消融治疗一名青壮年患者的大面积药物抵抗性肌内快流血管异常
Pub Date : 2024-04-12 DOI: 10.1097/jova.0000000000000088
Kristy Patel, Sean Schoeman, Anne Marie Cahill
Mitogen-activated protein 2 kinase (MAP2K) intramuscular high-flow vascular anomaly is a benign vascular lesion, thought to be congenital, with an indolent course. Years after initial presentation, symptoms may manifest due to abrupt growth. This report describes a case of a young female who presented with a MAP2K high-flow vascular anomaly with recalcitrant pain, resistant to a trial of Sirolimus and Trametinib. Significant lesion size reduction and pain resolution were achieved with a combination of preablation embolization followed by cryoablation. Follow-up of 5 years informs lesion reduction and stability. Using a multi-method approach (embolization then ablation) can be considered in the treatment of MAP2K high-flow vascular malformations resistant to medical therapy.
丝裂原活化蛋白 2 激酶(MAP2K)肌内高流量血管异常是一种良性血管病变,被认为是先天性的,病程缓慢。初次发病数年后,可能会因突然生长而出现症状。 本报告描述了一例年轻女性的病例,她患有 MAP2K 高流量血管畸形并伴有顽固性疼痛,对西罗莫司和曲美替尼的试验产生了耐药性。通过联合使用消融前栓塞术和低温消融术,病灶面积明显缩小,疼痛也得到缓解。5 年的随访结果显示,病灶缩小并趋于稳定。 在治疗对药物治疗耐药的MAP2K高流量血管畸形时,可以考虑使用多种方法(先栓塞再消融)。
{"title":"Large Medically Resistant Intramuscular Fast-Flow Vascular Anomaly in a Young Adult Patient Managed With Embolization and Cryoablation","authors":"Kristy Patel, Sean Schoeman, Anne Marie Cahill","doi":"10.1097/jova.0000000000000088","DOIUrl":"https://doi.org/10.1097/jova.0000000000000088","url":null,"abstract":"\u0000 \u0000 Mitogen-activated protein 2 kinase (MAP2K) intramuscular high-flow vascular anomaly is a benign vascular lesion, thought to be congenital, with an indolent course. Years after initial presentation, symptoms may manifest due to abrupt growth.\u0000 \u0000 \u0000 \u0000 This report describes a case of a young female who presented with a MAP2K high-flow vascular anomaly with recalcitrant pain, resistant to a trial of Sirolimus and Trametinib. Significant lesion size reduction and pain resolution were achieved with a combination of preablation embolization followed by cryoablation. Follow-up of 5 years informs lesion reduction and stability.\u0000 \u0000 \u0000 \u0000 Using a multi-method approach (embolization then ablation) can be considered in the treatment of MAP2K high-flow vascular malformations resistant to medical therapy.\u0000","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infantile Hemangioma with Minimal or Arrested Growth: Different Clinical Presentations in a Retrospective Case Series 生长缓慢或停止的婴儿血管瘤:回顾性病例系列中的不同临床表现
Pub Date : 2024-04-12 DOI: 10.1097/jova.0000000000000086
Jinia El-Feghaly, Molly Marous, Heidi Bai, M. Cordisco
Infantile hemangioma with minimal or arrested growth (IHMAG) has been established as a subtype of infantile hemangioma (IH) due to positive glucose transporter-1 staining; however, it is clinically differentiated by a proliferative component of <25% of its total surface area. IHMAG can be misdiagnosed as a capillary malformation, an IH precursor, a noninvoluting congenital hemangioma, or an arteriovenous malformation among others. In this case series, we aim to further illustrate the various clinical characteristics of IHMAG and the features that distinguish this unique entity from the other vascular entities. It is important to recognize the differentiating characteristics to avoid unnecessary evaluation and provide patients with the appropriate management plan. A retrospective chart review approved by the University of Rochester Medical Center Institutional Review Board was performed from January 2014 to December 2020, with the search terms: “infantile hemangioma with arrested or minimal growth,” “IHMAG” and “abortive hemangioma.” In total, 29 IHMAGs were identified in 27 patients. Charts were reviewed for demographic and clinical characteristics as well as workup, response to treatment, and outcomes. In total, we identified 29 IHMAGs in 27 patients. Female to male ratio was 2:1. Average gestational age was 40 weeks. Lesions were present at birth in 22/27 patients. Out of the 29 IHMAGs, 18 were focal (62%) and 11 were segmental (38%). In most patients, skin examination revealed fine telangiectatic patches with focal areas of bright red papules. Out of 29 IHMAGs, 20 involved the lower body and 18 were focal, whereas 11 were segmental. PHACES syndrome (posterior fossa anomalies, infantile hemangioma, arterial anomalies, cardiac anomalies, eye anomalies, and midline skin defects) was identified in 2 of 2 patients with facial segmental IHMAGs. LUMBAR syndrome (lower body infantile hemangiomas and other skin defects; urogenital anomalies and ulceration; myelopathy; bony deformities; anorectal malformations and arterial anomalies; and rectal anomalies) was ruled out in 2 of 2 patients with extensive IHMAGs involving the sacral area. Semicircular lipoatrophy was seen in 1 patient with segmental circumferential IHMAG of the leg. Ultrasonography was the most used modality. Out of 27 infants, 18 were treated with topical timolol, 4 were treated with oral propranolol, and 2 patients were treated with a combination of both. Trends of the epidemiologic, clinical, and prognostic data of our 27 cases are in concordance with prior reports on IHMAG, further consolidating our understanding of this peculiar entity. IHMAG typically presents as a telangiectatic pink to violaceous patch present at birth in term newborns predominantly involving the lower half of the body. It is important to keep a high index of suspicion for the other vascular anomalies in the differential diagnosis. A segmental IHMAG should prompt providers to screen for ass
由于葡萄糖转运体-1 染色阳性,具有极小或生长停滞的婴儿血管瘤(IHMAG)已被确定为婴儿血管瘤(IH)的一种亚型;然而,它在临床上的区别在于其增殖成分占总表面积的比例小于 25%。IHMAG可能被误诊为毛细血管畸形、IH前兆、非膨胀性先天性血管瘤或动静脉畸形等。在本病例系列中,我们旨在进一步说明 IHMAG 的各种临床特征以及将这种独特实体与其他血管实体区分开来的特征。认识这些鉴别特征对于避免不必要的评估和为患者提供适当的治疗方案非常重要。 经罗切斯特大学医学中心机构审查委员会批准,我们在 2014 年 1 月至 2020 年 12 月期间进行了一项回顾性病历审查,搜索关键词为:"婴儿血管瘤":"生长停止或极少的婴儿血管瘤"、"IHMAG "和 "中止性血管瘤"。总共在 27 名患者中发现了 29 个 IHMAG。我们对病历进行了审查,以了解人口统计学和临床特征以及检查、治疗反应和结果。 我们总共在 27 名患者中发现了 29 个 IHMAG。男女比例为 2:1。平均孕周为 40 周。22/27例患者出生时即有病变。在 29 例 IHMAG 中,18 例为局灶性(62%),11 例为节段性(38%)。大多数患者的皮肤检查显示有细小的毛细血管扩张斑块,病灶部位有鲜红色丘疹。在 29 例 IHMAG 中,20 例累及下半身,18 例为局灶性,11 例为节段性。在 2 名面部节段性 IHMAG 患者中,有 2 人被发现患有 PHACES 综合征(后窝异常、婴儿血管瘤、动脉异常、心脏异常、眼部异常和中线皮肤缺损)。在 2 例骶骨部位有广泛 IHMAGs 的患者中,有 2 例排除了 LUMBAR 综合征(下半身婴儿血管瘤和其他皮肤缺损;泌尿生殖器畸形和溃疡;脊髓病变;骨骼畸形;肛门直肠畸形和动脉畸形;直肠畸形)。一名腿部节段性环状 IHMAG 患者出现半圆形脂肪萎缩。超声检查是最常用的方法。在 27 名婴儿中,18 人接受了局部噻吗洛尔治疗,4 人接受了口服普萘洛尔治疗,2 名患者接受了两者的联合治疗。 27 例病例的流行病学、临床和预后数据趋势与之前有关 IHMAG 的报道一致,进一步巩固了我们对这一特殊病例的认识。IHMAG 通常表现为足月儿出生时出现的毛细血管扩张性粉红色至暴发性斑块,主要累及下半身。在鉴别诊断时,必须高度怀疑其他血管异常。节段性 IHMAG 应促使医疗机构筛查相关综合征,如 PHACES 和 LUMBAR。为了更好地阐明 IHMAG 及其相关异常的发病机制,有必要进行更多的研究。证据级别:原始报告(病例系列)。
{"title":"Infantile Hemangioma with Minimal or Arrested Growth: Different Clinical Presentations in a Retrospective Case Series","authors":"Jinia El-Feghaly, Molly Marous, Heidi Bai, M. Cordisco","doi":"10.1097/jova.0000000000000086","DOIUrl":"https://doi.org/10.1097/jova.0000000000000086","url":null,"abstract":"\u0000 \u0000 Infantile hemangioma with minimal or arrested growth (IHMAG) has been established as a subtype of infantile hemangioma (IH) due to positive glucose transporter-1 staining; however, it is clinically differentiated by a proliferative component of <25% of its total surface area. IHMAG can be misdiagnosed as a capillary malformation, an IH precursor, a noninvoluting congenital hemangioma, or an arteriovenous malformation among others. In this case series, we aim to further illustrate the various clinical characteristics of IHMAG and the features that distinguish this unique entity from the other vascular entities. It is important to recognize the differentiating characteristics to avoid unnecessary evaluation and provide patients with the appropriate management plan.\u0000 \u0000 \u0000 \u0000 A retrospective chart review approved by the University of Rochester Medical Center Institutional Review Board was performed from January 2014 to December 2020, with the search terms: “infantile hemangioma with arrested or minimal growth,” “IHMAG” and “abortive hemangioma.” In total, 29 IHMAGs were identified in 27 patients. Charts were reviewed for demographic and clinical characteristics as well as workup, response to treatment, and outcomes.\u0000 \u0000 \u0000 \u0000 In total, we identified 29 IHMAGs in 27 patients. Female to male ratio was 2:1. Average gestational age was 40 weeks. Lesions were present at birth in 22/27 patients. Out of the 29 IHMAGs, 18 were focal (62%) and 11 were segmental (38%). In most patients, skin examination revealed fine telangiectatic patches with focal areas of bright red papules. Out of 29 IHMAGs, 20 involved the lower body and 18 were focal, whereas 11 were segmental. PHACES syndrome (posterior fossa anomalies, infantile hemangioma, arterial anomalies, cardiac anomalies, eye anomalies, and midline skin defects) was identified in 2 of 2 patients with facial segmental IHMAGs. LUMBAR syndrome (lower body infantile hemangiomas and other skin defects; urogenital anomalies and ulceration; myelopathy; bony deformities; anorectal malformations and arterial anomalies; and rectal anomalies) was ruled out in 2 of 2 patients with extensive IHMAGs involving the sacral area. Semicircular lipoatrophy was seen in 1 patient with segmental circumferential IHMAG of the leg. Ultrasonography was the most used modality. Out of 27 infants, 18 were treated with topical timolol, 4 were treated with oral propranolol, and 2 patients were treated with a combination of both.\u0000 \u0000 \u0000 \u0000 Trends of the epidemiologic, clinical, and prognostic data of our 27 cases are in concordance with prior reports on IHMAG, further consolidating our understanding of this peculiar entity. IHMAG typically presents as a telangiectatic pink to violaceous patch present at birth in term newborns predominantly involving the lower half of the body. It is important to keep a high index of suspicion for the other vascular anomalies in the differential diagnosis. A segmental IHMAG should prompt providers to screen for ass","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140711898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychometric Evaluation of the “Providing Validation” Measure in Vascular Anomalies 血管异常 "提供验证 "测量的心理测量学评估
Pub Date : 2024-04-02 DOI: 10.1097/jova.0000000000000089
Bryan A. Sisk, Anna M. Kerr, Amy R. Newman, Dandan Chen, Jennifer W. Mack, B. Reeve
We assessed the psychometric properties of the “providing validation” subscale of PedCOM measures for parents of children with vascular anomalies and adult patients. A total of 139 adult patients and 78 parents completed surveys. The mean score for patients was 3.7 (standard deviation 1.0), and for parents was 4.0 (standard deviation 0.9). “Providing validation” measures demonstrated high internal consistency and good model fit to a unidimensional model for both patients and parents using confirmatory factor analysis. The measures also demonstrated convergent validity with co-administered measures. This study demonstrated the validity of “providing validation” measures for parents and adult patients with vascular anomalies.
我们评估了 PedCOM 测量中 "提供验证 "分量表的心理测量特性,调查对象为血管异常儿童的家长和成年患者。共有 139 名成年患者和 78 名家长完成了调查。患者的平均得分为 3.7(标准差为 1.0),家长的平均得分为 4.0(标准差为 0.9)。通过确证因子分析,患者和家长的 "提供验证 "量表显示出较高的内部一致性和良好的单维模型拟合度。这些测量指标还显示出了与其他测量指标的趋同效度。这项研究证明了 "提供验证 "测量法对血管异常患者父母和成年患者的有效性。
{"title":"Psychometric Evaluation of the “Providing Validation” Measure in Vascular Anomalies","authors":"Bryan A. Sisk, Anna M. Kerr, Amy R. Newman, Dandan Chen, Jennifer W. Mack, B. Reeve","doi":"10.1097/jova.0000000000000089","DOIUrl":"https://doi.org/10.1097/jova.0000000000000089","url":null,"abstract":"We assessed the psychometric properties of the “providing validation” subscale of PedCOM measures for parents of children with vascular anomalies and adult patients. A total of 139 adult patients and 78 parents completed surveys. The mean score for patients was 3.7 (standard deviation 1.0), and for parents was 4.0 (standard deviation 0.9). “Providing validation” measures demonstrated high internal consistency and good model fit to a unidimensional model for both patients and parents using confirmatory factor analysis. The measures also demonstrated convergent validity with co-administered measures. This study demonstrated the validity of “providing validation” measures for parents and adult patients with vascular anomalies.","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Neurotrophic Tyrosine Receptor Kinase-rearranged Neoplasm Resembling a Vascular Malformation 类似血管畸形的小儿神经营养酪氨酸受体激酶重排肿瘤
Pub Date : 2024-04-01 DOI: 10.1097/jova.0000000000000090
Mohammad Sadic, Alexander Hien Vu, Erol Bayraktar, Naomi Strubel, Sheel Sharma, Francine Blei, George Jour, Sandra Tomita
Pediatric neurotrophic tyrosine receptor kinase-rearranged spindle cell neoplasms are soft tissue neoplasms whose behaviors are not well understood. We provide a case presentation of such a tumor sharing features of a vascular malformation. Our patient is an 11-year-old female referred for a lesion clinically and radiologically concerning for a vascular tumor or malformation. Upon excision, next-generation sequencing revealed a laminA-neurotrophic tyrosine receptor kinase 1 fusion. Neurotrophic tyrosine receptor kinase-rearranged spindle cell neoplasms represent an emerging entity in children now being diagnosed with a variety of techniques including immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. Consideration for this tumor should be in the differential diagnosis of vascular skin lesions with unusual features on physical examination.
小儿神经营养酪氨酸受体激酶重排纺锤形细胞瘤是一种软组织肿瘤,其表现尚不十分清楚。我们提供了一例具有血管畸形特征的此类肿瘤的病例。我们的患者是一名 11 岁女性,因临床和影像学表现为血管瘤或血管畸形而转诊。切除术后,新一代测序发现了层粘连A-神经营养性酪氨酸受体激酶1融合。神经营养性酪氨酸受体激酶重排纺锤形细胞瘤是一种新出现的儿童肿瘤,目前可通过免疫组化、荧光原位杂交和新一代测序等多种技术进行诊断。在鉴别诊断体格检查有异常特征的血管性皮肤病变时,应考虑这种肿瘤。
{"title":"Pediatric Neurotrophic Tyrosine Receptor Kinase-rearranged Neoplasm Resembling a Vascular Malformation","authors":"Mohammad Sadic, Alexander Hien Vu, Erol Bayraktar, Naomi Strubel, Sheel Sharma, Francine Blei, George Jour, Sandra Tomita","doi":"10.1097/jova.0000000000000090","DOIUrl":"https://doi.org/10.1097/jova.0000000000000090","url":null,"abstract":"Pediatric neurotrophic tyrosine receptor kinase-rearranged spindle cell neoplasms are soft tissue neoplasms whose behaviors are not well understood. We provide a case presentation of such a tumor sharing features of a vascular malformation. Our patient is an 11-year-old female referred for a lesion clinically and radiologically concerning for a vascular tumor or malformation. Upon excision, next-generation sequencing revealed a laminA-neurotrophic tyrosine receptor kinase 1 fusion. Neurotrophic tyrosine receptor kinase-rearranged spindle cell neoplasms represent an emerging entity in children now being diagnosed with a variety of techniques including immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. Consideration for this tumor should be in the differential diagnosis of vascular skin lesions with unusual features on physical examination.","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapidly Growing Congenital Disseminated Pyogenic Granuloma in the Scalp Treated with Staged Embolization and Excision: A Case Report 采用分期栓塞和切除术治疗头皮快速生长的先天性播散性化脓性肉芽肿:病例报告
Pub Date : 2024-04-01 DOI: 10.1097/jova.0000000000000084
Michael Mohnasky, Jeyhan Wood, Elizabeth Nieman, Jennifer Brondon, Kamran Khan, Kyung Rae Kim
Pyogenic granulomas are common, acquired vascular lesions that most often arise spontaneously or in sites of previous trauma. However, there are reports of a few cases that describe a rare condition, congenital disseminated pyogenic granuloma (CDPG), in which an infant either is born with or shortly after birth develops multiple pyogenic granulomas. A hallmark of CDPG is negative staining for glucose transporter 1 (GLUT-1) on immunohistochemistry, which helps distinguish it from the more common multifocal infantile hemangiomas. Because few case reports have described CDPG, much is unknown about its characteristics, clinical course, and most effective treatment options. Here, we present a case of an infant with a unique presentation of CDPG with lesions that are atypically large and growing at a rapid pace. We also describe a novel approach to treating large pyogenic granulomas in CDPG via staged glue embolization and surgical excision.
化脓性肉芽肿是一种常见的后天性血管病变,多为自发性或在以前受过创伤的部位出现。不过,也有少数病例报告了一种罕见的情况,即先天性播散性化脓性肉芽肿(CDPG),婴儿出生时或出生后不久即出现多个化脓性肉芽肿。CDPG 的特征之一是免疫组织化学染色显示葡萄糖转运体 1(GLUT-1)呈阴性,这有助于将其与更常见的多灶性婴儿血管瘤区分开来。由于描述 CDPG 的病例报告很少,人们对其特征、临床过程和最有效的治疗方案还知之甚少。在此,我们介绍了一例表现独特的 CDPG 婴儿病例,该病例的病变异常巨大且生长迅速。我们还介绍了一种通过分期胶栓塞和手术切除治疗 CDPG 大型化脓性肉芽肿的新方法。
{"title":"Rapidly Growing Congenital Disseminated Pyogenic Granuloma in the Scalp Treated with Staged Embolization and Excision: A Case Report","authors":"Michael Mohnasky, Jeyhan Wood, Elizabeth Nieman, Jennifer Brondon, Kamran Khan, Kyung Rae Kim","doi":"10.1097/jova.0000000000000084","DOIUrl":"https://doi.org/10.1097/jova.0000000000000084","url":null,"abstract":"Pyogenic granulomas are common, acquired vascular lesions that most often arise spontaneously or in sites of previous trauma. However, there are reports of a few cases that describe a rare condition, congenital disseminated pyogenic granuloma (CDPG), in which an infant either is born with or shortly after birth develops multiple pyogenic granulomas. A hallmark of CDPG is negative staining for glucose transporter 1 (GLUT-1) on immunohistochemistry, which helps distinguish it from the more common multifocal infantile hemangiomas. Because few case reports have described CDPG, much is unknown about its characteristics, clinical course, and most effective treatment options. Here, we present a case of an infant with a unique presentation of CDPG with lesions that are atypically large and growing at a rapid pace. We also describe a novel approach to treating large pyogenic granulomas in CDPG via staged glue embolization and surgical excision.","PeriodicalId":74008,"journal":{"name":"Journal of vascular anomalies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of vascular anomalies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1